Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 6, 2009, Pages 406-415

  Björklund, Elisabet ^a   Matinlauri, Irma ⁱ   Tierens, Anne ^g   Axelsson, Susanne ^e   Forestier, Erik ^b   Jacobsson, Stefan ^c   Ahlberg, Åsa Jeppsson ^a   Kauric, Goran ^h   Mäntymaa, Pentti ^j   Osnes, Liv ^f   Penttilä, Tarja Leena ^k   Marquart, Hanne ^o   Savolainen, Eeva Riitta ^l,m   Siitonen, Sanna ⁿ   Torikka, Kerstin ^d   Mazur, Joanna ^p   Porwit, Anna ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c Laboratory of Clinical Chemistry Sahlgrenska   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h Hospital of North Norway   (Norway)

ⁱ KUOPIO UNIVERSITY HOSPITAL   (Finland)

^j TAMPERE UNIVERSITY HOSPITAL   (Finland)

^k TURKU UNIVERSITY HOSPITAL   (Finland)

^l OULU UNIVERSITY HOSPITAL   (Finland)

^m UNIVERSITY OF OULU   (Finland)

ⁿ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^o Rigshospitalet   (Denmark)

^p INSTITUTE OF MOTHER AND CHILD   (Poland)

more..

Author keywords

Childhood acute leukemia; Flow cytometry; Minimal residual disease; Quality assurance; Standardization

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW DISEASE; CHILD; CLINICAL ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEALTH PROGRAM; HUMAN; LABORATORY TEST; MALE; MEDICAL SOCIETY; MINIMAL RESIDUAL DISEASE; PRE B LYMPHOCYTE; PRE T LYMPHOCYTE; PRIORITY JOURNAL; QUALITY CONTROL; SCHOOL CHILD; STANDARDIZATION;

ADOLESCENT; BONE MARROW; BONE MARROW EXAMINATION; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM, RESIDUAL; PATHOLOGY, CLINICAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; QUALITY CONTROL;

EID: 67651205898     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181a1c0e8     Document Type: Article

References (30)

1. Campana D, Freitas RO, CoustanSmith E. Detection of residual leukemia with immunological methods-technical developments and clinical implications. Leuk Lymphoma. 1994;13:31-34.
2. Lanza F. Towards standardization in immunophenotyping hematological malignancies. How can we improve the reproducibility and comparability of flow cytometric results? Working Group on Leukemia Immunophenotyping. Eur J Histo Chem. 1996;40 (suppl 1) :7-14.
3. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. Leukemia. 1996;10:877-895.
4. Ruiz-Arguelles A, Duque RE, Orfao A. Report on the first Latin American consensus conference for flow cytometric immunophenotyping of leukemia. Cytometry. 1998;34:39-42.
5. Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 1998;351:550-554.
6. Cave H, van der Werfften B, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med. 1998;339:591-598.
7. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352: 1731-1738.
8. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96:2591-2596.
9. Schrappe M. Evolution of BFM trials for childhood ALL. Ann Hematol. 2004;83 (suppl 1) :S121-S123.
10. Schultz KR, Pullen DJ, Sather HN, et al. Risk- and responsebased classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007;109:926-935.
11. Macedo A, Orfao A, Gonzalez M, et al. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia. 1995;9:993-998.
12. Lucio P, Parreira A, van den Beemd MW, et al. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia. 1999;13:419-427.
13. Porwit-MacDonald A, Bjorklund E, Lucio P, et al. BIOMED- 1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia. 2000;14:816-825.
14. Lucio P, Gaipa G, van Lochem EG, et al. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 concerted action investigation of minimal residual disease in acute leukemia: International Standardization and Clinical Evaluation. Leukemia. 2001;15:1185-1192.
15. Dworzak MN, Froschl G, Printz D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002;99:1952-1958.
16. Campana D. Determination of minimal residual disease in leukemia patients. Br J Haematol. 2003;121:823-828.
17. Bjorklund E, Mazur J, Soderhall S, et al. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia. Leukemia. 2003;17:138-148.
18. Krampera M, Perbellini O, Vincenzi C, et al. Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. Haematologica. 2006;91:1109-1112.
19. Ruiz-Arguelles GJ, Fernandez-Lara D, Estrada-Gomez R, et al. Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance. Lab Hematol. 2007;13:22-26.
20. San Miguel JF, Ciudad J, Vidriales MB, et al. Immunophenotypical detection of minimal residual disease in acute leukemia. Crit Rev Oncol Hematol. 1999;32:175-185.
21. Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia. 2000;14: 2267-2275.
22. Lie SO, Abrahamsson J, Clausen N, et al. Long-term results in children with AML: NOPHO-AML Study Group-report of three consecutive trials. Leukemia. 2005;19:2090-2100.
23. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18: 547-561.
24. Jaffe E, Harris NSHVJ. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
25. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemia. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783-1786.
26. Altman DG. Practical Statistics for Medical Research. London: Chapman and Hall; 1991;403-409.
27. Guyatt G, Walter S, Shannon H, et al. Basic statistics for clinicians: 4. Correlation and regression. CMAJ. 1995;152: 497-504.
28. McGinn T, Wyer PC, Newman TB, et al. Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic). CMAJ. 2004;171:1369-1373.
29. Gaipa G, Basso G, Maglia O, et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia. 2005;19:49-56.
30. Dworzak MN, Gaipa G, Ratei R, et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible. Cytometry Part B: Clin Cytometry. 2008 [E-pub ahead of print].